Pine Valley Investments Ltd Liability Co Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Pine Valley Investments Ltd Liability Co reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,988 shares of the company's stock after selling 3,416 shares during the quarter. Johnson & Johnson comprises 1.0% of Pine Valley Investments Ltd Liability Co's investment portfolio, making the stock its 12th biggest holding. Pine Valley Investments Ltd Liability Co's holdings in Johnson & Johnson were worth $16,042,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of JNJ. State Street Corp increased its holdings in Johnson & Johnson by 0.9% in the third quarter. State Street Corp now owns 134,245,811 shares of the company's stock valued at $21,755,874,000 after buying an additional 1,154,088 shares in the last quarter. Geode Capital Management LLC increased its stake in Johnson & Johnson by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company's stock valued at $9,064,149,000 after purchasing an additional 1,004,763 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Johnson & Johnson by 10.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company's stock worth $2,744,979,000 after purchasing an additional 1,831,751 shares during the last quarter. FMR LLC boosted its position in Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company's stock worth $2,968,440,000 after purchasing an additional 1,265,748 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Johnson & Johnson by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock valued at $2,858,543,000 after buying an additional 102,502 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3 %

JNJ stock traded down $0.40 on Thursday, hitting $146.24. 6,166,939 shares of the company were exchanged, compared to its average volume of 7,118,662. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The business's fifty day moving average is $157.29 and its two-hundred day moving average is $156.35. The stock has a market capitalization of $352.09 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 2.66 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 earnings per share. As a group, research analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson's payout ratio is currently 71.78%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Citigroup reduced their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective for the company. Bank of America reaffirmed a "neutral" rating and issued a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday. Finally, Royal Bank of Canada raised their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $174.73.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.